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Abstract
Intercellular adhesion molecule 1 (ICAM-1) is a membrane-bound glycoprotein expressed on endothelial cells and
cells of the immune system. Human ICAM-1 mediates adhesion and migration of leucocytes, and is implicated in
inflammatory pathologies, autoimmune diseases and in many cancer processes. Additionally, ICAM-1 acts as
receptor for pathogens like human rhinovirus and Plasmodium falciparum malaria parasites. A group of related P.
falciparum erythrocyte membrane protein 1 (PfEMP1) domains, the DBLβ, mediates ICAM-1 binding of P. falciparum-
infected erythrocytes. This ICAM‑1-binding phenotype has been suggested to be involved in the development of
cerebral malaria. However, more studies identifying cross-reactive antibody and ICAM-1-binding epitopes and the
establishment of a clinical link between DBLβ expression and e.g. cerebral malaria are needed before the DBLβ
domains can be put forward as vaccine candidates and go into clinical trials. Such studies require availability of
functional recombinant ICAM-1 in large quantities. In this study, we compared recombinant ICAM-1 expressed in
HEK293 and COS-7 cells with mouse myeloma NS0 ICAM-1 purchased from a commercial vendor in terms of
protein purity, yield, fold, ability to bind DBLβ, and relative cost. We present a HEK293 cell-based, high-yield
expression and purification scheme for producing inexpensive, functional ICAM‑1. ICAM-1 expressed in HEK293 is
applicable to malaria research and can also be useful in other research fields.
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Introduction
ICAM-1 is a member of the immunoglobulin (Ig) superfamily
and is expressed by endothelial cells and leucocytes as a
membrane-bound protein containing five extracellular Ig-like
domains (D1-D5), a trans-membrane domain, and a
cytoplasmic domain. ICAM‑1 mediates adhesion and migration
of leukocytes by binding to leukocyte function-associated
antigen-1 (LFA‑1) and macrophage antigen-1 (Mac-1) [1,2]. It
is implicated in inflammatory pathologies, autoimmune
diseases, and many cancer processes [3]. It furthermore acts
as a receptor for human rhinovirus causing common cold [4–6]
and as a receptor for P. falciparum-infected erythrocytes (IEs)
binding to endothelial cells [7–20].
P. falciparum malaria remains a major health issue causing
~200 million cases of disease and ~700,000 deaths annually,
mainly among African children below 5 years-of-age [21].
Parasite virulence is closely related to the expression of
PfEMP1 on the surface of IEs mediating their adhesion to host
endothelium by binding to different vascular host receptors,
including ICAM‑1. IE sequestration leads to inflammation,
circulatory obstruction, and organ dysfunction [22]. ICAM-1
expressed on vascular endothelial cells has been suggested as
a receptor involved in the development of cerebral malaria, a
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severe and often fatal complication with IE sequestration in the
brain [7,9,11,19].
Several ICAM-1-binding PfEMP1 domains and a full length
PfEMP1 molecule have previously been characterized [18,23],
and we recently identified a conserved domain cassette (DC)
structure (DC4) in some of these [20]. DC4-containing PfEMP1
proteins share a particular ICAM‑1-binding phenotype
conferred by the DBLβ3_D4 domain of DC4. DC4 has been
linked to the pathogenesis of severe disease [24] and can
induce cross-reactive adhesion inhibitory antibodies [20].
However, more studies linking ICAM‑1-adhering IEs to severe
disease such as cerebral malaria and identifying ICAM-1-
binding PfEMP1 epitopes (not least epitopes inducing
adhesion-inhibitory antibodies) are needed before DBLβ3_D4
can be put forward as a vaccine candidate. Achievement of this
goal depends heavily on the availability of large quantities of
high-quality recombinant ICAM-1.
ICAM-1 expressed as a recombinant protein by mouse
myeloma NS0 cells can be purchased commercially and has
been used in various studies to demonstrate binding of
P. falciparum IEs to ICAM-1 [13–16]. Other studies have used
transfected CHO cells [17,18,20,25]. Finally, COS‑7 cells
transiently producing soluble ICAM-1 have also been widely
used [8,10,12,26]. Surprisingly, soluble recombinant ICAM-1
expressed in one of the most widely used transient expression
systems, human embryonic kidney (HEK) cells and derivatives
hereof [27] has only been used for malaria binding assays in
very few studies [20,23].
Recombinant protein yield is generally higher in HEK than
CHO cells [28], and can reach several hundred milligrams of
recombinant protein per litre of culture medium [29,30]. Thus
the HEK expression system has the potential to produce large
quantities of recombinant ICAM-1 as well as the ability to
produce recombinant proteins with appropriate human post-
translational modifications.
In this study, we compared ICAM-1 expression in HEK293,
COS-7, and mouse myeloma NS0 cells, in terms of protein
purity, yield, folding, the ability to bind a recombinant DC4-
containing PfEMP1 protein, and relative cost. We present a
HEK293 cell-based, high-yield expression and purification
scheme for producing inexpensive, functionally intact ICAM-1
able to bind the P. falciparum antigen PFD1235w-DBLβ3_D4.
Materials and Methods
Protein expression and purification
Recombinant ICAM-1-Fc chimera (ICAM-1-FcHEK293) was
made from expression in FreeStyle 293-F cells (Invitrogen).
ICAM-1 D1-D5 combined with the hinge region, CH2 and CH 3
of human IgG1 was cloned into a mammalian expression
vector holding a CMV promoter [8]. The vector was amplified in
MC1061/P3 E. coli cells and DNA was purified using EndoFree
Plasmid Maxi Kit (Qiagen). HEK293 cells in the exponential
growth phase were grown in Gibco FreeStyle 293 Expression
Medium (Invitrogen) until they reached a cell density of 1×106
cells/ml. The cells were transiently transfected using FreeStyle
MAX Reagent (Invitrogen) according to the manufacturer’s
instructions. Briefly, 120 µg DNA diluted in Gibco OptiPro SFM
(Invitrogen) were gently mixed with 120 µl FreeStyle MAX
Figure 1.  Purification of ICAM1-Fc expressed by HEK293 cells.  Data from exp. #1 is shown here as an example of purification
of ICAM-1-FcHEK293. (A) Dot blot showing 2 µl of cell supernatant at day of harvest, 2 µl diafiltrated supernatant (column input) and 2
µl column run-through. 1.8 µg and two ten-fold dilutions hereof of the eluted ICAM-1-Fc was dotted onto the membrane. ICAM-1-Fc
was detected using HRP-conjugated anti-human IgG antibody. (B) Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) gel electrophoresis of 5 µl protein marker (lane 1), 10 µl column input (lane 2), 10 µl column run-through (lane 3) and 9
µg eluted ICAM-1-Fc (lane 4+5). Samples were reduced using DTT (+) or non-reduced (−). Arrows indicate ICAM-1-Fc bands.
doi: 10.1371/journal.pone.0069999.g001
Expression of Recombinant ICAM-1
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e69999
Reagent diluted in OptiPro SFM and incubated for 10 min. The
mixture was added drop-wise to a flask containing 150 ml
HEK293 cells. The transfected cells were allowed to grow in
suspension for six days at 37° C in a humidified atmosphere of
5% CO2 on an orbital shaker platform rotating at 135 rpm. Six
days following transfection, the HEK293 cells were separated
from the ICAM-1-FcHEK293-containing supernatant by
centrifugation (20 min, 500 g). The supernatant was filtered
(0.2 µm), concentrated, and buffer-exchanged into 20 mM
sodium phosphate, pH 7. ICAM‑1-FcHEK293 was bound to a 1 ml
HiTrap Protein G HP column (GE Healthcare) connected to an
ÄKTAxpress controlled by UNICORN software (GE
Healthcare). ICAM-1-FcHEK293 was eluted from the column using
Glycine/HCl buffer (0.2M, pH 2.5) and neutralized immediately
using Tris/HCl buffer (1M, pH 9.0). Finally, purified ICAM-1-
FcHEK293 was buffer-exchanged into PBS. ICAM-1-Fc was also
expressed in COS-7 cells (ICAM-1-FCCOS-7), and purified as
previously described [8], where confluent COS-7 cells were
transfected using FuGENE6 transfection reagent (Roche)
according to the manufacturer’s instructions. Finally,
commercially available recombinant ICAM1-Fc (ICAM-1-FcNS0)
Figure 2.  Comparison of ICAM-1-Fc by Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-
PAGE).  SDS-PAGE gel electrophoresis of 5 µg of ICAM-1-Fc
expressed in HEK293 cells, COS-7 cells or in mouse myeloma
NS0 (R&D Systems) cells. 5 µl protein marker (M) was loaded
onto the gel. Samples were reduced using DTT (+) or non-
reduced (−). Arrows indicate ICAM-1-Fc bands.
doi: 10.1371/journal.pone.0069999.g002
produced in mouse myeloma cell line NS0 was purchased from
R&D Systems.
The ICAM-1-binding DBLβ3_D4 domain and the non-
ICAM‑1-binding DBLβ3_D5 domain of the PFD1235w var gene
from the 3D7 P. falciparum parasite [20] were cloned into
pET15b modified to encode an N-terminal 6xHis fusion tag,
expressed in Shuffle® T7 Express Competent E. coli
(Medinova), and purified as described [31].
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)
Recombinant ICAM-1-Fc proteins were separated by SDS-
PAGE under reducing (+DTT) and non-reducing conditions (-
DTT). Protein (5 µg) was loaded into each well on a NuPAGE®
Novex 4-12% Bis-Tris gel in MOPS SDS Running buffer
(Invitrogen) and detected using BioSafe Coomassie stain (BIO-
RAD). ProSieve Color Protein marker (Lonza) was used for
size estimation.
Dot blot
Dot blots were done by adding a 2-µl drop of purified protein
or cell pellet suspended in PBS +2% SDS onto a HybondTM-C
Extra membrane (Amersham BioSciences). The membrane
was blocked using TBST + 5% skimmed milk (1 h; room
temperature). Protein was detected by anti-human IgG-HRP
(Dako, 1:3000 in TBST; 1 h; room temperature) using a
chemiluminescence detection kit (Pierce).
Reactivity of monoclonal ICAM-1 antibodies
The reactivity of a panel of mouse anti-human ICAM-1
monoclonal antibodies (mAbs) with the ICAM-1-Fc proteins
was examined by ELISA. Maxisorp plates (Thermo Scientific)
were coated (overnight; 4° C) with ICAM-1-Fc (2 µg/well) in
Glycine/HCl buffer (0.1 M, pH 2.75) and blocked with blocking
buffer (PBS, 0.5 M NaCl, 1% Triton-X-100, 1% BSA, pH 7.2)
for 1 h at room temperature. The following mAbs were added
(1 h; room temperature) to each well: RR1/1 (1 µg; AH
Diagnostics), 84H10 (0.5 µg; AH Diagnostics), LB2 (0.3 µg; AH
Diagnostics), BBIG-I1 (2.5 µg; R&D Systems), 8.4A6 (0.5 µg;
SigmaAldrich), My13 (1 µg; Invitrogen) and 15.2 (0.5 µg; AbD
serotec). A mouse anti-human CD36 antibody (FA6.152,
Ramcon) was included as negative control (2.5 µg). The plates
were washed in PBS+1% Triton-X-100, and bound mAbs were
detected by anti-mouse Ig-HRP (Dako, 1:1000 in blocking
buffer; 1 h). The plates were developed using OPD tablets
(Dako) according to the manufacturer’s instructions. The optical
density (OD) value was read at 490 nm using a VERSAmax
microplate reader (Molecular Devises) and Softmax Pro v
4.7.1.
Malaria antigen-binding assay.  The malaria antigen
binding assay was performed using ELISA as described [20].
Briefly, Maxisorp plates were coated (overnight; 4° C) with
recombinant PFD1235w-DBLβ_D4 or DBLβ3_D5 (0.1 µg/well)
in Glycine/HCl buffer (0.1 M, pH 2.75) and blocked with
blocking buffer (PBS, 0.5 M NaCl, 1% Triton-X-100, 1% BSA,
pH 7.2). ICAM-1-Fc (0-1.5 µg/well) was added (1 h; room
temperature), followed by washing using PBS+1% Triton-
X-100. Bound ICAM-1-Fc was detected by HRP-conjugated
Expression of Recombinant ICAM-1
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anti-human-IgG (1:3000 in blocking buffer; 1 h), and the
reaction was developed using OPD as described above.
Figure 3.  Reactivity of monoclonal ICAM antibodies.  The reactivity of seven anti-human ICAM-1 specific monoclonal antibodies
(clones 15.2, RR1/1, 84H10, LB2, BBIG-I1, 8.4A6 and My13) against ICAM-1-Fc expressed in HEK293, COS-7 or mouse myeloma
NS0 (R&D Systems) cells were tested using ELISA. One CD36 specific monoclonal antibody (clone FA6.152) was included as
negative control. Data shown are the mean reactivity (three independent experiments) of the antibodies to ICAM-1. Errors indicate
S.D.
doi: 10.1371/journal.pone.0069999.g003
Figure 4.  Binding of the malaria PfEMP1 antigen DBLβ3_D4 to ICAM-1-Fc.  Concentration-dependent binding of recombinant
P. falciparum 3D7 PFD1235w DBLβ3_D4 to ICAM-1-FcHEK239, ICAM-1-FcCOS-7 and ICAM-1-FcNS0 (R&D Systems) by ELISA. The
binding of DBLβ3_D4 to ICAM-1-FcHEK239 was repeated in three independent experiments (mean and standard deviation shown)
while the assay using ICAM-1-FcCOS-7 and ICAM-1-FcNS0 (R&D Systems) was done one time each.
doi: 10.1371/journal.pone.0069999.g004
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Results and Discussion
Purity and yield of ICAM-1-Fc
Transfected HEK293 cells were grown for 6 days before
harvesting ICAM-1-FcHEK293 from the supernatant. Supernatant
ICAM-1-FcHEK293 could be detected by dot blotting before and
after buffer exchange and concentration (Figure 1A) but was
not visible by SDS-PAGE (Figure 1B, lane 2). Despite the
presence of protein contaminants in the supernatant before
purification, ICAM-1-FcHEK293 was the major protein species
eluted from the Protein G column yielding very pure protein
(Figure 1B, lanes 4–5). Purified ICAM-1-FcHEK293 was separated
both under reducing and non-reducing conditions on the SDS-
PAGE gel. A band shift was observed from ~100 kDa under
reducing to ~200 kDa under non-reducing conditions (Figure
1B, lanes 4-5). The protein size under reducing conditions was
larger than the estimated molecular weight (79 kDa) of ICAM-1-
Fc estimated from the protein sequence (http://web.expasy.org/
protparam/). Each ICAM-1 molecule has eight potential N-
glycosylation sites of which seven of them are glycosylated
when expressed in CHO cells [32]. The increased molecular
weight observed here is thus most probably due to
glycosylation of these sites. The difference between theoretical
and observed molecular weight corresponds well to the sizes of
the commercially available ICAM-1NS0 given by the
manufacturer. Under non-reducing conditions, the ICAM-1-Fc
is expected to be a dimer due to a disulfide bond between the
two Fc domains. This prediction corresponds well with the
observed molecular weight (~200 kDa) for the non-reduced
ICAM-1-Fc.
ICAM-1-FcHEK293 was expressed twice with cells grown in four
flasks containing 150 ml of culture. Cells from the four flasks
were pooled, centrifuged, and discarded. The supernatant was
buffer-exchanged and reduced to a volume of 200 ml, which
was loaded onto the protein G column. The yields of ICAM-1-
FcHEK293 in the two experiments were 7.1 mg and 7.0 mg,
respectively, corresponding to a yield of 11.8 mg/L and
11.6 mg/L. Re-purification on a protein G column of the
ICAM-1-FcHEK293 remaining in the column run-through (Figure
1A) yielded an additional 4.0 mg protein. Thus, the averaged
total protein yield was 15.1 mg/L. Subsequent expression runs
gave similar protein yields (data not shown). In comparison,
expression in COS-7 cells gave 1.3 mg ICAM-1-Fc per litre cell
culture supernatant (data not shown). The expression and
purification data of soluble ICAM1 in COS-7 cells have been
previously published [8].
Folding of ICAM-1-FcHEK293 resembles reference ICAM-1-
Fc
ICAM-1-Fc expressed in COS-7 cells and in mouse myeloma
NS0 cells have previously been shown to function as receptors
for PfEMP1 [8,10,12–16,26]. We therefore compared our
ICAM-1-FcHEK293 and ICAM-1-FcCOS-7 to commercial ICAM-1-
FcNS0 by SDS-PAGE and by their ELISA reactivity with a panel
of seven human ICAM-1-specific mouse mAbs. All three
proteins behaved similarly on SDS-PAGE showing the
expected molecular sizes under reducing (monomer) and non-
reducing (dimer) conditions (Figure 2). Contaminating bovine
IgG from the culture medium was present in ICAM-1-FcCOS-7
(Figure 2, lanes 4-5) and thus contributes to the 5 µg of total
protein loaded onto the gel. The proteins were recognized
equally well by all seven ICAM-1-specific mAbs, except for
8.4A6, which reacted less well with ICAM-1-FcCOS-7 (Figure 3).
The mAbs 15.2, RR1/1, 84H10, LB2, BBIG/I1 and My13
recognize conformational epitopes in the first Ig domain of
ICAM-1 [26,33,34], whereas mAb 8.4A6 recognizes a linear
penta-peptide present in the second Ig domain of ICAM-1 [34].
We conclude that the conformation of ICAM-1-FcHEK293
corresponds to that of ICAM-1-FcCOS‑7 and ICAM-1-FcNS0.
HEK293 cells produce functionally intact ICAM-1-Fc
binding a malaria antigen
Binding parameters of a single PfEMP1 domain has
previously been shown to be similar to that of a IT4 PfEMP1
ectodomain [23]. We have previously shown that the
DBLβ3_D4 domain of the PfEMP1 protein PFD1235w binds to
ICAM‑1, whereas the immediately downstream DBLβ3_D5
domain does not [20]. ICAM-1-FcHEK293 expressed in this study
was fully functional and bound to DBLβ3_D4 in a
concentration-dependent manner (Figure 4). In contrast,
DBLβ3_D5 did not bind to any of the ICAM‑1 constructs
(Figure 4). The molecular weights of all the ICAM-1 constructs
were the same, but ~20 kDa bigger than predicted, probably
due to glycosylation of the N-glycosylation sites. The nature of
sugar chains added to ICAM-1 differs significantly between
glycosylation site and the ICAM-1 expressing cell, hence
between expression systems [28,32]. These differences affect
the binding of ICAM-1 to some receptors (e.g., Mac-1) but not
others (e.g., LFA‑1) [35] and might regulate the biological
activity of ICAM-1 in vivo [32]. However, the role of ICAM-1
glycosylation in P. falciparum infections remains to be
investigated. The glycan profile of ICAM-1HEK239 has been
shown similar to that of ICAM-1COS-7 and less variant than that
of ICAM-1NS0 [29], but from our experiments these differences
did not seem to affect the ICAM-1 binding to DBLβ3_D4.
Expression of ICAM-1-Fc in HEK293 cells is cost-
effective
As reported above, we achieved yields of ICAM-1-FcHEK239
that were 10-fold higher than yields of ICAM-1-FcCOS-7. This
makes the HEK239 system very cost-effective. In our hands,
the cost of producing ICAM-1-FcHEK239 is about 24-fold lower
than ICAM-1-FcCOS-7, and about 90-fold lower than buying
ICAM-1-Fc from a commercial source (e.g. R&D Systems, list
price DKK. 2320). This estimate is based on the cost of cell
lines, culture flasks, media, transfection reagents, and columns
for purification, salaries and the needed equipment. It
furthermore assumes that standard laboratory equipment such
as laminar flow hoods, CO2 incubators, orbital shakers, and a
system for protein purification are available.
Conclusion
In this study we present a high-yield expression and
purification scheme for producing inexpensive, functionally
intact ICAM-1-Fc in transfected HEK293 cells. In addition to
Expression of Recombinant ICAM-1
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being useful in malaria research, the HEK239 cell-produced
protein might also be useful in other research areas, as ICAM‑1
also acts as a receptor for cells of the immune system and
viruses such as human rhinovirus.
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